Media Centre
Latest press releases
-
Imfinzi plus Imdelltra reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
-
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
-
Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy
-
Tezspire positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
-
AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes
-
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
